Merck looking at Seagen takeover bid in the wake of Clay Siegall’s resignation — report

Merck is evaluating a potential buyout of embattled Seattle biotech Seagen, according to a report from the Wall Street Journal on Friday morning. This is the newest development for the biotech after former CEO Clay Siegall stepped down from the company — while also forfeiting his board positions at other companies…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.